Abiraterone decanoate (Propella Therapeutics)

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameAbiraterone decanoate (Propella Therapeutics)
Drug Alias Name癸酸阿比特龙Long-acting IM depot injection of abiraterone decanoate (Propella Therapeutics)阿比特龙癸酸酯的长效肌注长效注射剂(Propella Therapeutics)癸酸阿比特龙(Propella Therapeutics)PRL-02 +[7] 
ClassificationSmall molecules > SteroidsSmall molecules > Prodrug
Mechanisms of ActionSteroid 17-alpha-hydroxylase inhibitors
TargetsSteroid 17-alpha-hydroxylase
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPuerto Rico +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPropella Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas (China) Investment Co LtdAstellas Pharma Global Development Inc
Inactive CompaniesN/A
Active IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A